Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

lupus

- PMLiVE

Gilead drives NASH development with insitro collaboration

Announcement comes days after Novo Nordisk deal

Infographic: Rheumatoid arthritis (RA)

An overview of the RA biologic patientOur RA market snapshot offers an introduction to the real world patient data collected by our Therapy Watch RA study. The snapshot looks at...

Research Partnership

Webcast: Navigating new frontiers: Ways to find space in the future RA market

In partnership with pharmaphorumView the webcast »The emergence of low-cost biosimilar versions of Humira and the new janus kinase (JAK) inhibitors, are shaking up a once-stable market.Although there are only...

Research Partnership

- PMLiVE

Gilead and Galapagos close in on filing for Xeljanz rival

Belgian biotech gearing up for first approval

- PMLiVE

Riva leaves Gilead to head Glenmark’s innovation spin-off

Company has own bispecific antibody platform

- PMLiVE

Gilead lead NASH drug flunks phase 3 test

Analysts suspect the setback could prompt Gilead to license other candidates

- PMLiVE

Gilead awaits CEO and readouts to revive fortunes

NASH and oral RA drugs set for crucial readouts

- PMLiVE

CAR-Ts go head-to-head after NICE clears Kymriah in DLBCL

Novartis agrees pricing deal with NHS England

- PMLiVE

Roche’s O’Day swaps big pharma for big biotech

Move to Gilead enforces reshuffle at neighbours Genentech

- PMLiVE

Gilead NASH drug clears mid-stage trial, but rivals are looming

Positive results to challenge Intercept in emerging disease area

- PMLiVE

Gilead and Galapagos JAK contender scores in RA trial

Trial adds to rivalry with AbbVie

- PMLiVE

Ipsen hires general manager, Laura Hamill joins Gilead and Orchard expands leadership team

The latest industry movers

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links